Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-30T22:33:24.147Z Has data issue: false hasContentIssue false

Diagnostic testing and antibiotic utilization among inpatients evaluated for coronavirus disease 2019 (COVID-19) pneumonia

Published online by Cambridge University Press:  28 December 2023

Megan R. Wimmer*
Affiliation:
Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin
Meggie Griffin
Affiliation:
Department of Emergency Medicine, University of Wisconsin–Madison, Madison, Wisconsin
Alex Peterson-Weber
Affiliation:
Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin
Lucas T. Schulz
Affiliation:
Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin
Ashlee G. Hamel
Affiliation:
Department of Pharmacy, Sentara Health, Norfolk, Virginia
Rebecca J. Schwei
Affiliation:
Department of Emergency Medicine, University of Wisconsin–Madison, Madison, Wisconsin
Karen Fong
Affiliation:
Department of Pharmacy, University of Utah Health, Salt Lake City, Utah
Donna R. Burgess
Affiliation:
University of Kentucky Healthcare, Lexington, Kentucky
Meghan Brett
Affiliation:
University of New Mexico Hospital, Albuquerque, New Mexico
Cory M. Hale
Affiliation:
Department of Pharmacy, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania
Marisa Holubar
Affiliation:
Stanford University School of Medicine, Stanford California
Rupali Jain
Affiliation:
University of Washington, Seattle, Washington
Rachel Larry
Affiliation:
Department of Pharmacy, Infirmary Health, Mobile, Alabama
Emily S. Spivak
Affiliation:
University of Utah Health, Salt Lake City, Utah
Helen Newland
Affiliation:
Barnes-Jewish Healthcare, St Louis, Missouri
Jessica Njoku
Affiliation:
Harris Health System, Houston, Texas
Michael Postelnick
Affiliation:
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois
Carla Walraven
Affiliation:
University of New Mexico Hospital, Albuquerque, New Mexico
Michael S. Pulia
Affiliation:
Department of Emergency Medicine, University of Wisconsin–Madison, Madison, Wisconsin
*
Corresponding author: Megan R. Wimmer; Email: MWimmer@uwhealth.org

Abstract

We evaluated diagnostic test and antibiotic utilization among 252 patients from 11 US hospitals who were evaluated for coronavirus disease 2019 (COVID-19) pneumonia during the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) omicron variant pandemic wave. In our cohort, antibiotic use remained high (62%) among SARS-CoV-2–positive patients and even higher among those who underwent procalcitonin testing (68%).

Type
Concise Communication
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Karaba, SM, Jones, G, Helsel, T, et al. Prevalence of coinfection at time of hospital admission in COVID-19 patients, a multicenter study. Open Forum Infect Dis 2020;8:ofaa578.CrossRefGoogle ScholarPubMed
Langford, BJ, So, M, Raybardhan, S, et al. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;26:16221629.10.1016/j.cmi.2020.07.016CrossRefGoogle ScholarPubMed
Lansbury, L, Lim, B, Baskaran, V, Lim, WS. Coinfections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020;8:266275.10.1016/j.jinf.2020.05.046CrossRefGoogle Scholar
Learn more about Vizient. Vizient website. https://www.vizientinc.com/about-us. Accessed April 26, 2023.Google Scholar
Metlay, JP, Waterer, GW, Long, AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America. Am J Respir Crit Care Med 2019;200:e45e67.CrossRefGoogle ScholarPubMed
Self, WH, Balk, RA, Grijalva, CG, et al. Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia. Clin Infect Dis 2017;65:183190.CrossRefGoogle ScholarPubMed
Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Center for Disease Control and Prevention website. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html. Accessed April 26, 2023.Google Scholar
Fabre, V Karaba, S, Amoah, J, et al. The role of procalcitonin results in antibiotic decision making in coronavirus disease 2019 (COVID-19). Infect Control Hosp Epidemiol 2022;43:570575.10.1017/ice.2021.175CrossRefGoogle ScholarPubMed
Lippi, G, Plebani, M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chmi Acta 2020;505:190191.CrossRefGoogle ScholarPubMed